Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.

This is a placebo-controlled, double-blind, gender balanced, within-subject study on the acute and 24 to 48 hour post dose effects (discontinuation syndrome) of MDMA on sleep architecture, water homeostasis and neurocognitive function. We will define the signs and symptoms of sleep disruption and time course of alterations in ADH levels and neurocognitive function occurring after administration of a single dose of MDMA in experienced users. The immediate effects of MDMA include euphoria and intoxication; at 24 hours after MDMA these positive effects are replaced by lowered mood and lethargy - we refer to these effects as a discontinuation syndrome. The pleasurable effects of MDMA are thought to be due to elevations of serotonin, norepinephrine and dopamine; the mechanisms of post-MDMA depression are unknown but may be due to relative serotonin depletion. Among its many functions serotonin maintains normal sleep architecture. The effects of MDMA discontinuation on sleep architecture will be assessed using comprehensive polysomnography and wrist actigraphy with measures obtained ~36 hours after a single dose of MDMA. Cognitive measurements will explore the acute effects of MDMA. MDMA can produce hyponatremia. In this study we will evaluate the effects of MDMA on ADH release, urine sodium excretion, and the relationship of gender to these effects.

Inclusion criteria

• Healthy men or women aged 18 to 50 years.
• If female: abstains from heterosexual sex, not of childbearing potential, or reports using an approved contraceptive.
• Experienced with MDMA
• Fluent in English.
• Willing and able to give written consent.
• Healthy without medical contraindications to MDMA administration determined by the following: medical history, physical examination, 12-lead EKG, hematology, blood chemistry, and urinalysis.
• Blood liver transaminase elevations up to 3 times the upper limit of normal.
• If female: negative pregnancy test at screening and at the beginning of each hospital admission.
• Negative urine drug test at screening and prior to each potential MDMA administration.

Exclusion criteria

• Current enrollment in a MDMA, alcohol, or other drug treatment program or current legal problems relating to MDMA, alcohol, or other drug use, including awaiting trial or supervision by a parole or probation officer.
• Participants with a past-history of using only low doses of MDMA
• Currently trying to quit MDMA use.
• Current dependence on any other psychoactive drug (including nicotine).
• Significant physical or psychiatric illness that might impair the ability to safely complete the study or that might be complicated by the study drugs, including prior seizures (after age 8) or other active neurological disease or clinically significant abnormalities on physical examination or screening laboratory values.
• Likelihood of needing medications to treat an illness during the study period.
• Body Mass Index > 30 or < 18.
• HIV seropositive by self-report.
• If female: pregnancy or lactation.
• History of serious adverse event or hypersensitivity to MDMA.
• Currently taking any medication other than over-the-counter non-steroidal anti-inflammatories, topical medications, inhaled asthma therapy, and over-the-counter non-sedating antihistamines.
• Male neck size ≥ 17 inches, female neck size ≥ 16 inches
• Modified Mallampati class ≥ 3.
• Recent travel within 3 days to or from a different time zone, other than Mountain Standard Time.
• Any other medical or psychosocial condition that would preclude useful, safe, or consistent participation.